Navigation Links
Actinium Pharmaceuticals Announces New Round of Financing
Date:9/21/2012

NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced  that it has engaged Laidlaw & Company (UK) Ltd. and launched a new round of fundraising that will culminate in a going public transaction. 

The Company intends to raise up to $20 million in new funds to be used for further clinical development of Actimab-A™ and Iomab-B™, Actinium's clinical stage drug candidates for treatment of hematologic malignancies, and continued preclinical development of additional drug candidates in solid cancer indications as well as for general working purposes.

"With this capital raise we will be able to progress our pipeline further in terms of generating proof of concept results for our Actimab-A™ program in elderly acute myeloid leukemia and advance our Iomab-B™ program into a registration  trial to enable a bone marrow transplant in patients otherwise ineligible for this curative procedure," said Jack Talley, Actinium's CEO. 

Laidlaw & Company (UK) Ltd., founded in 1878, is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private and public institutions, as well as high net worth individual investors.

Under the proposed terms of the offering, accredited investors will receive units consisting of Company's common stock and warrants.  This offering will culminate in the Company becoming a publicly traded entity on a US stock exchange targeted for later this year.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr.
Tel:  203-258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. 

 


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
2. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
3. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
6. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
7. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
8. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
9. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
10. Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop companion diagnostic for guiding Multiple Myeloma treatments
11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... With ... community have raised more than $15,000 in just a couple of weeks for ... grappling matches and world-class instructor seminars, organizers expect to double those initial funds ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... York, NY (PRWEB) , ... September 19, 2017 ... ... firm, announced today the addition of strategic marketing leader, Denise Flannery, to its ... Strategic Marketing, Brand and Management Consultant, Denise will work with clients across different ...
(Date:9/19/2017)... ... 19, 2017 , ... PAPA Healthcare, Inc. announced today, the ... Healthcare helps fill gaps, provide essential insights, and improve productivity.” The story ... leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home Infusion ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 , ... ... has settled over 175,000 debt accounts, translating to in excess of $835 million in ... card debt and other unsecured loans are some of the categories of debt settled ...
Breaking Medicine News(10 mins):